In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at ...

Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and ...

A first-in-class monoclonal antibody has shown significant reductions in skin disease in patients with cutaneous lupus erythematosus (CLE). Litifilimab met the primary endpoint of reduction of disease ...

Cybin Inc (NASDAQ:HELP) is among the best psychedelic stocks to buy in 2026. Toronto, Canada-based Cybin Inc. is also known ...

Novo Nordisk A/S (NYSE:NVO) and The United Laboratories International Holdings Limited said Wednesday that their jointly ...

Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates ...

Biohaven Ltd. (NYSE:BHVN) is one of the 10 Small–Cap Stocks Insiders Are Buying Recently. On March 19, 2026, Biohaven Ltd.

Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2 ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

In this analysis, researchers aimed to quantify and bring attention to the time burden experienced by cancer patients enrolled in phase 2 clinical trials.

- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo ...